Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Ann Oncol. 2022 Mar 16;33(6):638–648. doi: 10.1016/j.annonc.2022.03.005

Table 2:

The association of HPV16 SNPs with patient prognosis

Overall Survival4
Position Viral Gene/Region Minor Allele(s) MAF (%) Hazard Ratio (95% CI)2 P 3
1053 E1 C 5.5 3.75 (1.77–7.95) 0.0099
44101 L2 G 2.1 5.32 (1.91–14.81) 0.0120
4539 L2 C 1.3 6.54 (2.03–21.08) 0.0117
5050 L2 A/T 2.0 6.53 (2.34–18.24) 0.0030
5254 L2 A 1.0 7.76 (2.41–24.98) 0.0030
5962 L1 C 3.4 4.40 (1.88–10.31) 0.0110
60251 L1 T/C 2.9 5.71 (2.43–13.41) 0.0008
7173 URR A 1.0 9.90 (3.05–32.12) 0.0007
1

D2 sublineage defining SNP

2

Univariable Cox proportional hazards model

3

False discovery rate (FDR) corrected

4

384 participants were included in the analysis; 70 deaths; median follow-up time was 4.06 years (IQR: 2.25 to 6.79)

Abbreviations: MAF, minor allele frequency; CI, confidence interval